DCT and cancer: Previous preclinical vaccination studies in mice have demonstrated the ability of Ad5-TRP2 and Ad5-mTRP2 to protect against B16.F10 metastases (55, 58); however, their ability to effectively combat solid B16.F10 tumors in a therapeutic setting has rarely been investigated, possibly because B16.F10 solid tumors are notoriously difficult to eradicate with cancer vaccines in general.